KEGG DRUG: Catumaxomab

DRUG: Catumaxomab

Entry

D09207                      Drug

Name

Catumaxomab (INN);
Removab (TN)

Remark

ATC code:

L01FX03

Efficacy

Antineoplastic, Anti-CD3 antibody, Anti-EpCAM antibody

Disease

Malignant ascites

Type

Monoclonal antibody, bispecific trifunctional antibody

Target

EPCAM (CD326) [HSA:4072] [KO:K06737]
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]

Pathway

hsa04640

Hematopoietic cell lineage

hsa04660

T cell receptor signaling pathway

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX03 Catumaxomab
      D09207  Catumaxomab (INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Cell adhesion molecules: Ig superfamiy
   CAMs
    EPCAM (CD326)
     D09207  Catumaxomab (INN)
  Other cell surface molecules
   CD molecules
    CD3
     D09207  Catumaxomab (INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D09207

Other DBs

CAS:	509077-98-9

PubChem:

96025887

LinkDB

» Japanese version » Back

DBGET integrated database retrieval system